Perez-Garcia JM, Llombart-Cussac A, G Cortes M, Curigliano G, et al. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase trial. Eur J Cancer 2021;148:382-394.
PMID: 33794440